BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14738143)

  • 1. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients.
    Martinelli G; Cocorocchio E; Saletti PC; Orecchia R; Bernier J; Tradati N; Santoro P; Robertson C; Peccatori FA; Zucca E; Cavalli F
    Leuk Lymphoma; 2003 Nov; 44(11):1919-23. PubMed ID: 14738143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
    Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
    Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
    Bates NP; Williams MV; Bessell EM; Vaughan Hudson G; Vaughan Hudson B
    J Clin Oncol; 1994 Feb; 12(2):288-96. PubMed ID: 7509382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
    Horning SJ; Hoppe RT; Mason J; Brown BW; Hancock SL; Baer D; Rosenberg SA
    J Clin Oncol; 1997 May; 15(5):1736-44. PubMed ID: 9164180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
    Horning SJ; Hoppe RT; Hancock SL; Rosenberg SA
    J Clin Oncol; 1988 Dec; 6(12):1822-31. PubMed ID: 2462025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?
    Gobbi PG; Federico M
    Crit Rev Oncol Hematol; 2012 Apr; 82(1):18-24. PubMed ID: 21592816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease.
    Moody AM; Pratt J; Hudson GV; Smith P; Lamont A; Williams MV
    Clin Oncol (R Coll Radiol); 2001; 13(4):262-8. PubMed ID: 11554622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
    Gobbi PG; Pieresca C; Frassoldati A; Carotenuto M; Di Renzo N; La Sala A; Berté R; Avanzini P; Federico M; Silingardi V; Ascari E
    J Clin Oncol; 1996 Feb; 14(2):527-33. PubMed ID: 8636767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.